The role of CD33 as therapeutic target in acute myeloid leukemia

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 7, 2014, Pages 715-718

  Walter, Roland B ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myeloid leukemia; Antibody; Antibody drug conjugate; Bispecific antibody; Bispecific T cell engager; CD33; Chimeric antigen receptor; Gemtuzumab ozogamicin; Immunotherapy

Indexed keywords

ANTIBODY CONJUGATE; BISPECIFIC ANTIBODY; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER IMMUNOTHERAPY; DRUG ACCUMULATION; DRUG TARGETING; HEMATOPOIESIS; HUMAN; INDUCTION CHEMOTHERAPY; INTERNALIZATION; REVIEW; TREATMENT OUTCOME; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE;

HUMANS; LEUKEMIA, MYELOID, ACUTE; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84902472791     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.909413     Document Type: Review

References (16)

1. Cowan AJ, Laszlo GS, Estey EH, et al. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed) 2013;18(4):1311-34
2. Hills RK, Petersdorf S, Estey EH, et al. The addition of gemtuzumab ozogamicin (GO) to induction chemotherapy reduces relapse and improves survival in patients without adverse risk karyotype: results of an individual patient meta-analysis of the five randomised trials [abstract]. Blood 2013;122(21):356
3. Borthakur G, Rosenblum MG, Talpaz M, et al. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/ rGEL), in patients with advanced myeloid malignancies. Haematologica 2013;98(2):217-21
4. Kung Sutherland MS, Walter RB, Jeffrey SC, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122(8):1455-63
5. Walter RB, Press OW, Bernstein ID. Antibody-based therapeutics targeting CD33, CD45, and CD66. In: Andreeff M, editor. Targeted therapy of acute myeloid leukemia. 1st edition. Springer, New York, NJ; 2014; In press
6. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1(2):118-29
7. Walter RB. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Rev Hematol 2014; In press
8. Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013;27(5):1107-15
9. Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123(3):356-65
10. Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014;123(4):554-61
11. Arndt C, von Bonin M, Cartellieri M, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013;27(4):964-7
12. Arndt C, Feldmann A, von Bonin M, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia 2014;28(1):59-69
13. Fry TJ, Mackall CL. T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2013;2013:348-53
14. Marin V, Pizzitola I, Agostoni V, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 2010;95(12):2144-52
15. Dutour A, Marin V, Pizzitola I, et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33+ acute myeloid leukemia. Adv Hematol 2012;2012:683-065
16. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014; In press